ABSTRACT
OBJECTIVE:To study in vitro effects of tanshinoneⅡA to reverse multiple drug resistance. METHODS:MCF-7/ADM cells and A549/DDP cells were cultured with 0 [20 mg/L doxorubicin(ADM)or cisplatin(DDP),negative control],5 mg/ml tanshinone ⅡA(combined with 20 mg/L ADM or DDP)for 24 and 48 h. Then MTT method was used to determine cell viability, and polymerase chain reaction(PCR)was adopted to detect mRNA expressions of cell cycle control protein CDC25A and cell cy-clin dependent kinase (CKD2). RESULTS:Compared to the negative control,after MCF-7/ADM cells and A549/DDP cells were cultured with tanshinone ⅡA for 24 and 48 h,cell viability was weaker,also were mRNA expressions of CDC25A and CKD2. There were statistical differences(P<0.01). CONCLUSIONS:Tanshinone ⅡA combined with ADM or DDP can inhibit the viabili-ty of cell line MCF-7/ADM and cell line A549/DDP,decrease expression of CDC25A,CKD2 mRNA in cells and reverse multiple drug resistance in malignant tumors.
ABSTRACT
Objective To study the change of DNA polymerase beta and XRCC1's expression during malignant celI differentiation.Methods The Eca-109 cells were divided inm 2 groups:differentiation group which cultured with 8-Br-cAMP and control group.The 2 groups cells were cultured 48h simultaneously.The immunocytochemistry was performed to detect the expression of DNA polymerase beta and XRCC1.Results Compared with control group,the expression of DNA polymerase beta and XRCC1 was decreased simultaneously(P＜0.05).Conclusion The differentiation agent can down-regulate the expression of DNA polymerase beta and XRCC1,suggesting that overexpressed DNA polymerase beta and XRCC1 maybe result in mutator phenotype.
ABSTRACT
Purpose:To study the characteristics of biological distribution in vivo and therapeutic efficacy of 125 I-anti-alpha-fetoprotein(AFP) antibody when administrated by the hepatic artery , and discussion of multi-modal therapy by transcatheter arterial chemoembolization(TACE) and immunization therapy. Methods:21 patients with moderately and advanced primary liver cancer (PLC) were treated by 125 I-anti -alpha-fetoprotein which was administered via hepatic artery, together with TACE and CD3AK cell by intravenous infusion to,detect the pharmacokinetic parameters and metabolism for 125 I-anti-AFP in vivo, and observe the efficacy of multi-modal treatment. Results:The radioactivity half-life time of ?phase (T 1/2 ?) and ? phase ( T 1/2 ?) for 125 I-anti-AFP antibodies was 1.85?1.79 and 156.46?65 hr,respectively; half-excretion time from urine was 94 hr, radiation intensity measured at body surface of organ suggested that the accumulated radioactivity was stronger and longer in the liver was than other organ.TPECT for tumour:liver ratio was 2.1?0.6. The efficacy for the treated group and the control group was respectively 61.9%(13/21) and 25.0%(5/20),the one-year cumulative survival rate of the treated group and the control group was also 61.9% and 25.0%.Conclusions: 125 I-anti-AFP via hepatic artery was able to concentrate electively in the tumour ,thereby bringing about a continuous internal irradiation for the tumour.This combined treatment is an effective method for PLC.